CAMBRIDGE, Mass., April 2, 2019 /PRNewswire/ -- Blueprint Medicines
Corporation (NASDAQ: BPMC), a precision therapy company
focused on genomically defined cancers, rare diseases and cancer
immunotherapy, today announced the closing of its previously
announced underwritten public offering of 4,662,162 shares of its
common stock at a public offering price of $74.00 per
share, including the exercise in full by the underwriters of their
option to purchase additional shares of common
stock. Blueprint Medicines estimates net proceeds from the
offering will be approximately $327.2 million, after deducting
underwriting discounts and commissions and estimated offering
expenses.
![Print Print](https://mma.prnewswire.com/media/221118/blueprint_medicines_logo.jpg)
Goldman Sachs & Co. LLC and Cowen and Company, LLC
acted as joint book-running managers for the
offering. Guggenheim Securities, LLC and Wedbush Securities
Inc. acted as co-lead managers for the offering. A
registration statement on Form S-3 (File No. 333-216573) relating
to these securities has been previously filed with
the Securities and Exchange Commission (SEC) and has
become effective. This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
A copy of the final prospectus supplement relating to the
offering has been filed with the SEC and may be obtained
from Goldman Sachs & Co. LLC by mail at Prospectus
Department, 200 West Street, New York,
NY 10282, by telephone at (866) 471-2526, by fax at (212)
902-9316, or by email at prospectus-ny@ny.email.gs.com, or from
Cowen and Company, LLC, c/o Broadridge Financial Services, 1155
Long Island Avenue, Edgewood, NY
11717, Attention: Prospectus Department, by telephone at (631)
274-2806, or by fax at (631) 254-7140.
About Blueprint Medicines
Blueprint Medicines is a precision therapy company striving to
improve human health. With a focus on genomically defined cancers,
rare diseases and cancer immunotherapy, we are developing
transformational medicines rooted in our leading expertise in
protein kinases, which are proven drivers of disease. Our uniquely
targeted, scalable approach empowers the rapid design and
development of new treatments and increases the likelihood of
clinical success. Blueprint Medicines is currently advancing four
investigational medicines in clinical development, along with
multiple research programs.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding the estimated net proceeds from the public offering;
future expectations, plans and prospects for Blueprint Medicines
and the timing of these events; and Blueprint Medicines' strategy,
business plans and focus. The words "may," "will," "could,"
"would," "should," "expect," "plan," "anticipate," "intend,"
"believe," "estimate," "predict," "project," "potential,"
"continue," "target" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions. These and other risks and uncertainties are
described in greater detail in the section entitled "Risk Factors"
in Blueprint Medicines' Annual Report on Form 10-K for the fiscal
year ended December 31, 2018, as
filed with the SEC on February 26,
2019, the prospectus supplement related to the public
offering and other filings that Blueprint Medicines has made or may
make with the SEC in the future. Any forward-looking statements
contained in this press release represent Blueprint Medicines'
views only as of the date hereof and should not be relied upon as
representing its views as of any subsequent date. Blueprint
Medicines explicitly disclaims any obligation to update any
forward-looking statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-of-common-stock-300823256.html
SOURCE Blueprint Medicines